Larson Financial Group’s Gain Therapeutics GANX Stock Holding History

Larson Financial Group’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19	Hold	10	–	–	﹤0.01%	3585
2025 Q4	$32	Buy	+10	New	+$27	﹤0.01%	3401

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Larson Financial Group's GANX Position: Q1 2026 in Review

Larson Financial Group held its Gain Therapeutics (GANX) position steady in Q1 2026 at 10 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #3585.

Larson Financial Group first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $32 in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Larson Financial Group held 10 shares of Gain Therapeutics worth $19 as of Q1 2026.
Larson Financial Group left its Gain Therapeutics share count unchanged in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3585 holding.
Larson Financial Group first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
Larson Financial Group's Gain Therapeutics position peaked at $32 in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.